Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (930)	2/6/2002 1:51:22 AM
From: scaram(o)uche	Respond to of 2243

boards.fool.com Other companies have also recognised the value of our joint venture partners, most recently Eli Lilly and Amgen with Isis; GlaxoSmithKline with INEX; Pfizer with Athersys; Sanofi Synthelabo with Atrix; Abbott with Idun. (snip) Products under development 52 Stage of clinical development 3 Phase III 15 Phase II 8 Phase I 26 Pre-clinical

To: scaram(o)uche who wrote (930)	2/6/2002 1:51:31 AM
From: aknahow	Respond to of 2243

BGEN is most likely bidder. Antegren 100% ownership would remove serious threat to having to share MS market with Antegren/Avonex combination or worse Antegren alone. BGEN recently changed its' tone slightly to saying that it would consider purchases from one of saying it believed internal development was the best path.

To: scaram(o)uche who wrote (930)	2/6/2002 2:01:51 AM
From: Spekulatius	Respond to of 2243

<<Well, they're going to get bids. >> I sure hope so.I never invested in ELN because earnings were overstated through capitalized R&D expenses (this is what these joint ventures were created for). However,it appears to me that these JV's are no shams. ELN has developed real products, using the biotechs JV. its funny, that the JV business model was "approved" for years and years and now gets flamed because of "Enronitis". At a little more than 2x revenues, ELN's market cap is now very low, compared to slower growth pharma (5x revenues). Good or bad accounting, ELN has real drugs in the market and real drugs in the pipeline and smart investors or a smart pharma CEO will recognize this. I own a few ELN shares now.

To: scaram(o)uche who wrote (930)	2/6/2002 2:21:13 AM
From: WhatsUpWithThat	Respond to of 2243

Even if earnings are overstated by a third (as per the article), pretty good PE here... WUWT

To: scaram(o)uche who wrote (930)	2/6/2002 2:31:06 AM
From: John Metcalf	Respond to of 2243

"If we got a bid, management would not stand in the way," said Mr Lynch. Message 17019433 Well, they're going to get bids. Geeze, at $4B market cap, even a concrete company would bid for them. But, assuming any bidder would be a pharmaceutical, an acquisition of Elan would be accretive to earnings at 3-4 times the current share price, and that's without allowing for cash on hand, plant and equipment, sales force, intellectual property, and upside from 55 JV's. Let the bidding begin, probably at $50 USD.